Online inquiry

IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5488MR)

This product GTTS-WQ5488MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5488MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4628MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ13775MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ14845MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ7031MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ12976MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ6298MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ7819MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ11678MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW